Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 6/20 | 0.50 |
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TK2 | O00142 | 4/20 | 0.33 |
| ▸ | TK1 | P04183 | 3/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709476 | 0.82 | HPRT1 (0.47) | HPRT1NOS1 | |
| SCHEMBL417578 | 0.80 | HPRT1 (0.60) | HPRT1NOS1 | |
| SCHEMBL713228 | 0.79 | HPRT1 (0.47) | HPRT1NOS1 | |
| Hydrochloric Acid SCHEMBL10507812 | 0.79 | HPRT1 (0.59) | HPRT1NOS1 | |
| SCHEMBL7745028 | 0.79 | HPRT1 (0.64) | HPRT1NOS1 | |
| Phosphoric Acid SCHEMBL571369 | 0.76 | HPRT1 (0.64) | HPRT1NOS1 | |
| SCHEMBL712025 | 0.75 | HPRT1 (0.54) | HPRT1TSHRTK1 | |
| SCHEMBL8362521 | 0.74 | PNP (0.50) | — | |
| SCHEMBL146837 | 0.73 | HPRT1 (0.58) | HPRT1TK1NOS1 | |
| SCHEMBL7223272 | 0.73 | HPRT1 (0.49) | HPRT1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576763-B1 | Stereospecific acylation; viricides for herpes and retroviruses | MEDIVIR AB (SE) | 2003-06-10 | — | — | US | claimed |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8124609-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-7432274-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2008-10-07 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-11-10 | — | — | US | disclosed |
| US-6878844-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-04-12 | — | — | US | disclosed |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-12-09 | — | — | US | disclosed |
| US-20040132749-A1 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-07-08 | — | — | US | disclosed |
| US-6613936-B1 | Herpes and retroviral infections; diester derivatives of H2G bearing specific combinations of an amino acid ester and a fatty acid ester, improved oral bioavailability; 9-(2-(butyryloxymethyl)-4-(L-isoleucyloxy)butyl)guanine | MEDIVIR AB (SE) | 2003-09-02 | — | — | US | disclosed |
| US-6576763-B1 | Stereospecific acylation; viricides for herpes and retroviruses | MEDIVIR AB (SE) | 2003-06-10 | — | — | US | disclosed |
| EP-0888348-B1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020188125-A1 | Acyclic nucleoside derivatives | MEDIVIR AB | 2002-12-12 | — | — | US | disclosed |
| US-6255312-B1 | VIRICIDES | MEDIVIR AB (SE) | 2001-07-03 | — | — | US | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
| EP-0888348-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 1999-01-07 | — | — | EP | disclosed |
| EP-0880521-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | Medivir Aktiebolag (SE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030051-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997030052-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | HPRT1 19/4885DUT 64/4885CYP2C9 1284/4885 |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | HPRT1 16/4885DUT 59/4885CYP2C9 1282/4885 |
| US-20040132749-A1 | Acyclic nucleoside derivatives | NSUN2, NUDT1, PNP | HPRT1 25/4885DUT 35/4885CYP2C9 1497/4885 |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | HPRT1 33/4885DUT 60/4885CYP2C9 1222/4885 |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | ASNS, NUDT1, PNP | HPRT1 32/4885DUT 90/4885CYP2C9 754/4885 |
| US-20020188125-A1 | Acyclic nucleoside derivatives | NSUN2, NUDT1, PNP | HPRT1 20/4885DUT 38/4885CYP2C9 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.